Means and methods for manufacturing highly pure neurotoxin

摘要

The present invention relates to an antibody which specifically binds to unprocessed and/or partially processed neurotoxin polypeptide or an antibody which specifically binds an epitope consisting of a peptide having an amino acid sequence as shown in any one of SEQ ID NOs: 1 to 16 and to methods for the manufacture of such antibodies. Moreover, the present invention relates to a composition comprising processed neurotoxin polypeptide free of unprocessed or partially processed neurotoxin polypeptide and a method for manufacturing said neurotoxin polypeptide based on the antibodies of the invention. The present invention also relates to the use of the aforementioned antibody for separating processed neurotoxin polypeptides from unprocessed or partially processed neurotoxin polypeptides or for determining unprocessed or partially processed neurotoxin polypeptides. The present invention relates to a method for the manufacture of a medicament.

主权项

1. A pharmaceutical composition comprising proteolytically processed, biologically active dichain neurotoxin, wherein the composition is free of detectable amounts of partially processed or unprocessed neurotoxin polypeptides, wherein the proteolytically processed, biologically active dichain neurotoxin is obtained by the steps of:
a) contacting a solution comprising a mixture of processed and partially processed and/or unprocessed neurotoxin polypeptides with an antibody which has been raised against a peptide immunogen comprising the amino acid sequence of SEQ ID NO: 25; b) allowing the binding of the antibody to the unprocessed and/or partially processed neurotoxin polypeptides whereby complexes comprising the antibody and partially processed or unprocessed neurotoxin polypeptides are formed; and c) removing the complexes formed in step b) to obtain a solution of processed, active dichain neurotoxin, wherein the solution is free of detectable amounts of unprocessed and/or partially processed neurotoxin polypeptides; and d) formulating the solution of processed neurotoxin polypeptides obtained in step c) with at least one stabilizer of the biologically active dichain neurotoxin selected from protein stabilizers and non-protein stabilizers in pharmaceutically acceptable diluents, carriers, and/or adjuvants.